Skip to content

Clinical trial of Zhixue Quyu Mingmu Tablet in the treatment of ocular fundus hemorrhage after its release

Taking the improvement of visual acuity as the main index to evaluate the effect of Zhixue Quyu Mingmu tablet in the treatment of submacular hemorrhage caused by various reasons. The syndrome types of TCM belong to yin deficiency and hyperactivity of liver and collateral vessel syndrome of heat injury.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035098
Enrollment
Unknown
Registered
2020-07-31
Start date
2020-08-20
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Submacular hemorrhage

Interventions

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with submacular hemorrhage in at least one eye; 2. Those who meet the syndrome differentiation criteria of yin deficiency and liver hyperactivity and heat injury of collaterals; 3. Over 18 years old; 4.Best corrected visual acuity (BCVA) measured by visual acuity chart: the letters of BCVA can be clearly seen by standard logarithmic visual acuity chart, ranging from 0.05 (including 0.1) to 0.6; 5. The refractive stroma is clear and does not interfere with fundus examination and fundus fluorescein angiography; 6. Patients should have good compliance with the observation and evaluation of the efficacy of the researchers; 7. Those who did not participate in other clinical trials within 2-4 weeks before treatment; 8. Those who sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Wet age-related macular degeneration was completely scarred without bleeding and exudation; 2. Fundus refractive stroma unclear (such as vitreous hemorrhage, cataract) affect the fundus condition of the observer; 3. Severe cardiovascular and cerebrovascular diseases, liver, kidney and hematopoiesis diseases; 4. Mental patients; 5. Severe allergy to sodium fluorescein injection; 6. Risk of thrombosis 7. Patients who are participating in clinical trials of other drugs; patients who use the same kind of traditional Chinese medicine and other treatments; or those who quit halfway.

Design outcomes

Primary

MeasureTime frame
Vision improvement within 6 months;

Countries

China

Contacts

Public ContactYouxin Chen

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

chenyouxinpumch@163.com+86 13801025972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026